Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2016-02-23 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 4D and 31 December 2015 Half Year Financial Report 23 pages 5.3MB
Regulatory Filings
2016-02-23 English
Partnership to promote BREVAGenplus 2 pages 100.5KB
Capital/Financing Update Classification · 70% confidence The document is an ASX announcement dated 22 February 2016 from Genetic Technologies Limited. It announces a partnership with IndyCar driver Pippa Mann to promote the company's breast cancer risk assessment test, BREVAGen plus. The content is promotional and marketing-related, focusing on the partnership details, the product, and the athlete's background. There are no financial statements, regulatory filings, voting results, or management changes discussed. The document is a corporate announcement about a marketing partnership rather than a financial report, regulatory filing, or governance document. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to company activities that could impact capital or market positioning, but since it is primarily a marketing partnership announcement without direct financing or capital structure changes, the confidence is moderate. However, none of the other categories fit better, and CAP is the closest match for company activity announcements outside of financial results or governance changes.
2016-02-21 English
Settlement & Release Agreement with Hendrix Genetics B.V. 1
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated 5 February 2016 regarding the execution of a Settlement and Release Agreement between Genetic Technologies Limited and Hendrix Genetics B.V. It mentions the dismissal of legal action and confidentiality of terms. The content is a legal settlement announcement rather than a financial report, earnings release, or management discussion. It does not contain financial statements, voting results, or regulatory certifications. The document is short (3808 characters) and is a specific announcement about legal settlement. Therefore, it fits best under Legal Proceedings Report (LTR).
2016-02-04 English
Appendix 4C - 31 December 2015 12 pages 122.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 December 2015' and contains detailed operational and financial information for Genetic Technologies Limited for the quarter ending December 31, 2015. It includes financial summaries, operational highlights, scientific study publications, and business updates relevant to the quarter. The presence of substantive financial data and analysis for a period shorter than a full fiscal year, along with the quarterly timeframe, clearly identifies this as an Interim / Quarterly Report. It is not a brief announcement or a certification, nor is it a full annual report or earnings release. Therefore, the correct classification is Interim / Quarterly Report (IR). Q2 2016
2016-01-26 English
Change in substantial holding 7 pages 1.9MB
Regulatory Filings
2016-01-17 English
Changes to Company Secretary 1 page 301.5KB
Regulatory Filings
2016-01-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.